Form 4: Royalty Pharma Executive Sells Shares Under 10b5-1 Plan

Royalty Pharma plc executive Marshall Urist reported the sale of 9,099 Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Summary

• Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 9,099 Class A Ordinary Shares on July 1, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on February 12, 2026.
• The shares were sold at a weighted average price of $55.8802, with individual sales ranging from $55.69 to $56.14 per share.
• Following these sales, Urist directly owns 0 Class A Ordinary Shares and indirectly owns 19,020 Class A Ordinary Shares through an IRA.
• Additional holdings include limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares exchangeable into 1,356,528 Class A Ordinary Shares, with Class E shares subject to vesting conditions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the sale of shares by a key executive, despite the use of a 10b5-1 plan. The scale reflects the lack of new financial information and the inherent caution associated with insider selling.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related sales.
• The executive continues to hold significant indirect beneficial ownership through an IRA and other exchangeable interests.

Negatives

• A notable number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale of 9,099 shares represents a reduction in direct beneficial ownership by a senior officer.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The Class E Ordinary Shares held by the reporting person are subject to vesting conditions, introducing uncertainty regarding their ultimate ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.
• The reported price is a weighted average, with shares sold in multiple transactions at prices ranging from $55.69 to $56.14 per share.
• The holder undertakes to provide full information regarding the number of shares sold at each separate price upon written request.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the pharmaceutical and biotech sectors. Investors often scrutinize these sales for insights into management's confidence in the company's future prospects, though 10b5-1 plans are designed to mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of reduced confidence by management, potentially impacting short-term share price. However, the 10b5-1 plan mitigates this concern to some extent.
• Employees: The sale by a senior executive may not have a direct impact, but could influence morale if perceived negatively.
• Creditors/Suppliers: No direct impact expected as the filing concerns equity transactions.

Next Steps

• The reporting person may continue to execute trades under the existing 10b5-1 plan.
• The company may receive requests for detailed pricing information regarding the executed transactions.

Key Dates

Keywords

Royalty Pharma, RPRX, Form 4, Insider Trading, 10b5-1 Plan, Share Sale, Marshall Urist, Class A Ordinary Shares, Beneficial Ownership